Long-term efficacy and safety of once-daily fosamprenavir 1400 mg boosted by ritonavir 100 mg: The BOLD100 study

International Journal of STD and AIDS

Volumn 23, Issue 3, 2012, Pages

  Blick, G ^a   Greiger Zanlungo, P ^b   Gretz, S ^a   Han, J ^c   Dupree, D ^c   Garton, T ^a   Yau, L H ^d   Wine, B C ^d   Pakes, G E ^d  

^a Circle Medical LLD ^*  (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c Mount Vernon Hospital USA   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Antiretroviral therapy; Fosamprenavir; HIV; Once daily; Ritonavir

Indexed keywords

DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR PLUS RITONAVIR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; PROTEINASE INHIBITOR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; VIRUS RNA; ZIDOVUDINE;

ADULT; AGED; ARTICLE; BRONCHITIS; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NAUSEA; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD; VOMITING;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARBAMATES; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; LIPIDS; MALE; MIDDLE AGED; PHOSPHORIC ACID ESTERS; RETROSPECTIVE STUDIES; RITONAVIR; RNA, VIRAL; SULFONAMIDES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84860913087     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2009.009161     Document Type: Article

References (19)

1. Gathe JC Jr, Ive P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 2004;18:1529-37
2. Sale M, Sadler BM, Stein DS. Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir. Antimicrob Agents Chemother 2002;46:746-54
3. Ruane PJ, Luber AD, Wire MB, et al. Plasma amprenavir pharmacokinetics and tolerability following administration of 1400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers. Antimicrob Agents Chemother 2007;51:560-5
4. Smith KY, Weinberg WG, DeJesus E, et al. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther 2008;5:1-10
5. Muret P, Montange D, Bettinger D, et al. Assessment of amprenavir plasma Cmin levels in patients receiving once-daily fos-amprenavir in combination with either 100 or 200 mg ritonavir. Eighth International Workshop on Clinical Pharmacology of HIV Therapy, Budapest, 16-18 April 2007 [abstract/poster 26]
6. DeWit S, Poll B, Necsoi C, Clumeck N. Fosamprenavir boosted with a single 100 mg capsule of ritonavir as part of a once daily first line regimen in naïve patients. Eighth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 12-16 November 2006 [abstract/poster P17]
7. Carosi G, Lazzarin A, Stellbrink H, et al. Efficacy and safety of fosamprenavir {thorn} ritonavir (FPV/r) 700 mg/100 mg twice daily (BID) versus FPV/r 1400 mg/100 mg once daily (QD) with ABC/3TC QD over 24 weeks. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 48th Annual Meeting/Infectious Diseases Society of America/46th Annual Meeting, Washington, DC, 25-28 October 2008 [abstract/poster H-1244]
8. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation 2002;106:3143-421
9. DeJesus E, Sloan L, Sension M, et al. 96-Week efficacy/safety data comparing two doses of ritonavir (/r) to boost once-daily (QD) fosamprenavir (FPV), used in combination with abacavir (ABC)/lamivudine (3TC). Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 48th Annual Meeting/Infectious Diseases Society of America/46th Annual Meeting, Washington, DC, 25-28 October 2008 [abstract/poster H-1246]
10. Wire MB, Shelton MJ, Studenberg S. Fosamprenavir: clinical pharmacokinectics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet 2006;45:137-68
11. Cooper CL, van Heeswijk RPG, Gallicano K, Cameron DW. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis 2003;36:1585-92
12. Parks D, Jennings H, Taylor C, et al. Steady-state pharmacokinetics (PK) of amprenavir (APV), tenofovir (TDF), emtricitabine (FTC), and ritonavir (RTV) in HIV{thorn} patients stabilized on fosamprenavir (FPV) 1400 mg {thorn} FTC/TDF 200/300 mg QD boosted by RTV 100 mg QD (TELEX II). Eighth International Workshop on Clinical Pharmacology of HIV Therapy, Budapest, Hungary, 16-18 April 2007 [abstract/poster 22]
13. Cohen C, DeJesus E, La Marca L, et al. Switching from a 200 mg ritonavir (RTV)-boosted fosamprenavir (FPV) regimen (700 mg/100 mg BID or 1400 mg/200 mg QD) to a 100 mg RTV-boosted FPV regimen (1400 mg/ 100 mg QD) yields similar efficacy and safety. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 48th Annual Meeting/Infectious Diseases Society of America/46th Annual Meeting. Washington, DC, 25-28 October 2008 [abstract/poster H-1250e (latebreaker)]
14. Jayaweera D, Pakes G. Improved triglycerides after reducing the ritonavir (RTV) boosting dose from 200 mg to 100 mg once daily (QD) in HIV{thorn} patients stabilized (viral load,50 c/mL) on QD RTV-boosted fosamprenavir (FPV) 1400 mg {thorn} abacavir (ABC) 600 mg/lamivudine (3TC)300 mg. American College of Clinical Pharmacy Annual Meeting-2008, Louisville, KY, 19-22 October 2008 [abstract/poster no. 99]
15. Dubé MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naïve subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005;19:1807-18
16. Van Leth F, Hall DB, Lange JMA, Reiss P. Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine. HIV Med 2006;7:347-50
17. Van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral therapy-naive patients infected with HIV-1. PLoS Med 2004;1:064-74
18. Montes ML, Pulido F, Barros C, et al. Lipid disorders in antiretroviral-naïve patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors. J Antimicrob Chemother 2005;55:800-4
19. Orman JS, Perry CM. Tipranavir. A review of its use in the management of HIV infection. Drugs 2008;68:1435-63.